Allan GM, Finley CR, Ton J, Perry D, Ramji J, Crawford K, Lindblad AJ, Korowynk C, Kolber MR. Systematic review of systematic reviews for medical cannabinoids. Canadian family physician 2018; 64: e78-e94.

Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk B, Johnson M, Sacks HS. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-Analysis of Individual Patient Data. J Pain 2015; 16: 1221-1232.

Andresen SR, Bing J, Hansen RM, Biering-Sørenson F, Hagen EM, Rice AS, Nielsen JF, Bach FW, Finnerup NB. Ultramicronized palmitoylethanolamide in Spinal Cord Injury Neuropathic Pain: A Randomized, Double-blind, Placebo-controlled Trial. Pain 2016; 157: 2097-103.

Andresen SR, Biering-Sorensen F, Hagen EM, Nielsen JF, Bach FW, Finnerup NB. Cannabis use in persons with traumatic spinal cord injury in Denmark. J Rehabil Med 2017; 49: 152-160.

Arsenault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325: 1212.

Atakan, Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241-254.

Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: A review of the literature. Curr Psychiatry Rep 2017; 19:23.

Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidol reduces the anxiety induced by stimulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219-26.

Boland EG, Bennett MI, Allgar V, and Boland JW. Cannabinoids for adult cancer-related pain: a systematic review and meta-analysis. BMJ supportive and palliative care 2020; 0:1-11. doi:10.1136/bmjspcare-2019-002032

Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology and Implications for the Acute Care Setting. Pharmacology and Therapeutics 2017; 42: 180-188.

Brubacher JF, Chan H, Erdelyi S, Macdonald S, Asbridge M, Mann RE, et al. Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study. Society for the Study of Addiction 2019; 114: 1616-1626.

Bruce D, Brady JP, Foster E, Shattell M. Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses. Journal of alternative and complementary medicine 2018; 24: 146-153.

Cardenas DD, Jensen MP. Treatments for chronic pain in persons with spinal cord injury: A survey study. Journal of Spinal Cord Medicine 2006; 29:109-117.

Canadian Centre on Substance Abuse (CCSA) Synthetic Cannabinoids in Canada. CCENDU Bulletin March 2014. Retrieved on February 13, 2020 from:

Cannabis Act. S.C., c. 16 (2018). Retrieved on 13-02-2020 from:

Carlini EA, Cunha JM. Hypnotic and Antiepileptic effects of cannabidiol. J Clin Pharmacol 1981; 21: 417S-427S.

Drossel C, Forchheimer M, Meade MA. Characteristics of Individuals with Spinal Cord Injury Who Use Cannabis for Therapeutic Purposes. Top Spinal Cord Inj Rehabil 2016; 22 :3-12.

Habibi R, Hoffman SJ. (2018) Legalizing Cannabis Violates the UN Drug Control Treaties, But Progressive Countries like Canada Have Options. Ottawa Law Review. Retrieved from:

Hagenbach U, Luz S, Ghafoor N, Berger J, Grotenhermen F, Brenneisen R, et al. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551-62.

Hall W, & Degenhardt L. Adverse health effects of non-medical cannabis use. The Lancet 2009; 374: 1383-1391.

Hawley LA, Ketchum JM, Morey C, Collins K, Charlifue S. Cannabis Use in Individuals With Spinal Cord Injury or Moderate to Severe Traumatic Brain Injury in Colorado. Archives of physical medicine and rehabilitation 2018; 99:1584-1590.

Health Canada (2013) Health Canada warns of risks related to synthetic marihuana products. Last accessed 13/2/2020 from:

Health Canada (2016) The Final Report of the Task Force on Cannabis Legalization and Regulation. Ottawa; Health Canada publications. Last accessed 13/2/2020 from:

Health Canada (2018) Information for health care professionals. Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa; Health Canada publications. Last accessed January 26, 2021 from:

Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing Smoked Cannabis for Chronic Noncancer Pain. Can Fam Physician 2014; 60: 1083-1090.

Kogel R, Johnson P, Chintam R, Robinson C, Nemchausky B. Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. Am J Ther 1995; 2: 799-805.

Malec J, Harvey R, Cayner J. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 1982; 63: 116-8.

Manini, A.F., Yiannoulos, G., Bergamaschi, M.M., Hernandez, S., Olmedo, R., Barnes, A.J., Winkel, G., Sinha, R., Jutras-Aswad, D., Huestis, M.A., and Hurd, Y.L. (2015). Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med; 9(3):204-10.

McPartland JM, McKernan KJ. (2017) Contaminants of Concern in Cannabis: Microbes, Heavy Metals and Pesticides. In: Chandra S., Lata H., Elsohly M. (eds) Cannabis Sativa L. – Botany and Biotechnology. Springer, Cham

Moulin, DE, Boulanger, A, Clark, AJ, Clarke, H, Dao, T, Finley, GA, Furlan, A, Gilron, I, Gordon, A, Morley-Forster, PK, Sessle, BJ, Squire, P, Stinson, J, Taenzer, P, Velly, A, Ware, MA, Weinberg, EL, and Williamson, OD. (2014). Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag; 19(6):328-335.

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based Medicine for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2018; 3. Art. No: CD012182 DOI: 10.1002/14651858.CD012182.pub2

Nabata KJ, Tse EK, Nightingale TE, Lee AHX, Eng JJ, Queree M, Walter M, Krassioukov AV. (2020). The Therapeutic Potential of Cannabinoids in People with Spinal Cord Injury: A systematic review. Curr Neuropharmacol 2020 Apr 19; Online ahead of print.

National Academies of Sciences, Engineering, and Medicine (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi: 10.17226/24625.

National Center for Environmental Health (2018) Synthetic cannabinoids: What are they? What are their effects? | HSB | NCEH. Retrieved February 18, 2020, from:

Nightingale TE, Tejpar T, O’Connell C, Krassioukov AV. (2020). Using Cannabis to Control Blood Pressure After Spinal Cord Injury: A Case Report. Ann Intern Med; 173(8):668-670.

Office of Medical Cannabis/Ministry of Health, Welfare and Sports of the Netherlands (2019). Medical Cannabis: Information for Doctors/Healthcare Professionals. Retrieved February 1, 2020 from:

Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010; 91: 703-7.

Rodriguez de Fonseca F, del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: Physiology and pharmacology. Alcohol & Alcoholism 2005; 40: 2-14.

Rintala DH, Fiess RN, Tan G, Holmes SA, and Bruel BM. Effect of Dronabinol on Central Neuropathic Pain After Spinal Cord Injury. American Journal of Physical Medicine and Rehabilitation 2010; 89: 840-848.

Shroff FM. Experiences with Holistic Health Practices among Adults with Spinal Cord Injury. Rehabilitation Process and Outcome 2015; 4:27-34.

van Os, J, Bak, M, Hanssen, M, Bijl, RV, de Graaf, R, Verdoux, H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156(4):319-27.

Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29.

Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, Clark CR, Ghinai I, Holzbauer SM, Navarette KA, Danielson ML, Ellington S, Moritz ED, Petersen EE, Kiernan EA, Baldwin GT, Briss P, Jones CM, King BA, Krishnasamy V, Rose DA, Reagan-Steiner S. Hospitalization and Deaths Associated with Evali. The New England Journal of Medicine 2020; 382:1589-1598.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use. A Systematic Review and Meta-Analysis. JAMA 2015; 313: 2456-2473.

Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9: 506-521.

Wilsey B, Marcotte TD, Deutscha, R, Zhao H, Prasad A. An exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. Journal of Pain 2016; 17: 982-1000.